Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

Merck pursues new cancer combinations, prediction markets put pharma’s confidential information in focus and personalized ...

CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...

Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third ...

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...

The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?

Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...

Success in women’s oncology isn’t just about buying patients more time but making those added months or years feel as close to normal as possible, according to Dr. Shweta Jain, vice president of ...

As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners ...

Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it ...